Which Direct-Acting Oral Anticoagulant Is Best for Preventing Recurrent Venous Thromboembolism?

Apixaban demonstrates slightly superior efficacy and safety over rivaroxaban and warfarin.

Direct-acting oral anticoagulants (DOACs) have demonstrated superiority compared with warfarin in safety and efficacy for treating patients with venous thromboembolism (VTE). However, individual DOACs have not been compared head to head, so evidence on efficacy and bleeding has been limited to observational studies. In this latest observational study, researchers examined diagnosis codes from Medicare and commercial insurance databases for 160,000 adults started on oral anticoagulation (apixaban, rivaroxaban, or warfarin) after hospitalization for new-onset VTE. Those with end-stage renal disease were excluded.

During median follow-up of ≈6 months, apixaban recipients were significantly less likely than rivaroxaban and warfarin recipients to…

Reviewing Authors

Nolan J. Mischel, MD

Disclosures

Nothing to disclose

Nolan J. Mischel, MD

Disclosures

Nothing to disclose

Allan S. Brett, MD

Disclosures

Nothing to disclose

Allan S. Brett, MD

Disclosures

Nothing to disclose

Which Direct-Acting Oral Anticoagulant Is Best for Preventing Recurrent Venous Thromboembolism?

Topics

Reviewing Authors